Two companies announced on Thursday that the heart-disease drug they had been developing failed its Phase 3 trial.
Source link
Trending
- Decoding the link between autoimmune diseases and blood cancers
- NBE releases round 1 indicative seat matrix for FNB counselling 2025, 684 seats available across 32 specialities
- Meta says its new AI model is ready to compete on coding
- Character.AI enters the microdrama arena with its own productions, but there’s a twist
- Tata’s Assam semiconductor plant to receive Rs 14,044 crore in government incentives
- The U.S. and China are today’s leaders in AI. These countries could be the next-stage champions.
- Soybean sowing gains pace, acreage seen surpassing last year
- Huge crowds gather in Mashhad for burial of Iran’s supreme leader
